Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVS Corvus Pharmaceuticals	$4.26 +1.7%	$3.62	$1.75 ▼ $10.00	$290.40M	0.57	766,978 shs	490,369 shs
FHTX Foghorn Therapeutics	$4.39 +1.6%	$4.14	$2.94 ▼ $10.25	$244.70M	3.04	142,004 shs	61,315 shs
INMB INmune Bio	$8.02 +4.2%	$7.56	$4.32 ▼ $10.50	$184.33M	1.55	289,894 shs	670,791 shs
TNYA Tenaya Therapeutics	$0.62 +5.2%	$0.49	$0.36 ▼ $4.06	$101.23M	2.91	2.61 million shs	1.69 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVS Corvus Pharmaceuticals	0.00%	+7.16%	+16.07%	-11.23%	+105.39%
FHTX Foghorn Therapeutics	0.00%	-3.14%	-2.48%	-6.09%	-17.71%
INMB INmune Bio	0.00%	+1.05%	-2.04%	+0.39%	-9.31%
TNYA Tenaya Therapeutics	0.00%	-6.67%	+31.56%	-18.97%	-82.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRVS Corvus Pharmaceuticals	2.684 of 5 stars	3.5	2.0	2.7	2.5	0.6
FHTX Foghorn Therapeutics	2.488 of 5 stars	3.6	2.0	2.7	1.7	0.6
INMB INmune Bio	1.8929 of 5 stars	3.6	0.0	2.6	1.7	0.6
TNYA Tenaya Therapeutics	3.703 of 5 stars	3.5	3.0	2.8	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	252.11% Upside
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	176.20% Upside
INMB INmune Bio	3.17	Buy	$22.80	184.29% Upside
TNYA Tenaya Therapeutics	3.00	Buy	$6.25	904.34% Upside

Current Analyst Ratings Breakdown

Latest TNYA, CRVS, FHTX, and INMB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	CRVS Corvus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$12.00 ➝ $11.00
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	CRVS Corvus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $17.00
5/9/2025	TNYA Tenaya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/30/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
4/30/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/25/2025	TNYA Tenaya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/23/2025	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/23/2025	FHTX Foghorn Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform	$9.00
4/23/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$9.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$0.79 per share	N/A
FHTX Foghorn Therapeutics	$23.50M	10.41	N/A	N/A	($1.83) per share	-2.40
INMB INmune Bio	$50K	3,686.63	N/A	N/A	$2.07 per share	3.87
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$2.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRVS Corvus Pharmaceuticals	-$27.03M	-$0.98	N/A	N/A	N/A	N/A	-70.71%	-45.90%	8/5/2025 (Estimated)
FHTX Foghorn Therapeutics	-$98.43M	-$1.36	N/A	N/A	N/A	-357.53%	N/A	-30.98%	8/6/2025 (Estimated)
INMB INmune Bio	-$30.01M	-$1.93	N/A	N/A	N/A	N/A	-117.48%	-78.96%	7/30/2025 (Estimated)
TNYA Tenaya Therapeutics	-$124.08M	-$1.16	N/A	N/A	N/A	N/A	-86.17%	-71.14%	8/14/2025 (Estimated)

Latest TNYA, CRVS, FHTX, and INMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/8/2025	Q1 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.13	N/A	-$0.13	N/A	N/A
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million
5/7/2025	Q1 2025	TNYA Tenaya Therapeutics	-$0.18	-$0.24	-$0.06	-$0.24	N/A	N/A
3/27/2025	Q4 2024	INMB INmune Bio	-$0.54	-$0.40	+$0.14	-$0.40	N/A	N/A
3/25/2025	Q4 2024	CRVS Corvus Pharmaceuticals	-$0.12	-$0.18	-$0.06	-$0.18	N/A	N/A
3/17/2025	Q4 2024	TNYA Tenaya Therapeutics	-$0.32	-$0.28	+$0.04	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRVS Corvus Pharmaceuticals	N/A	0.92	0.92
FHTX Foghorn Therapeutics	N/A	4.77	4.77
INMB INmune Bio	N/A	2.59	2.59
TNYA Tenaya Therapeutics	N/A	5.27	5.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRVS Corvus Pharmaceuticals	46.64%
FHTX Foghorn Therapeutics	61.55%
INMB INmune Bio	12.72%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
CRVS Corvus Pharmaceuticals	28.50%
FHTX Foghorn Therapeutics	7.58%
INMB INmune Bio	35.70%
TNYA Tenaya Therapeutics	48.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRVS Corvus Pharmaceuticals	30	68.17 million	44.15 million	Optionable
FHTX Foghorn Therapeutics	120	55.74 million	50.57 million	Optionable
INMB INmune Bio	10	22.98 million	14.37 million	Optionable
TNYA Tenaya Therapeutics	110	162.67 million	53.27 million	Optionable

TNYA, CRVS, FHTX, and INMB Headlines

Recent News About These Companies

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Buy" by Analysts

June 12, 2025 | marketbeat.com

Head-To-Head Survey: Tenaya Therapeutics (NASDAQ:TNYA) versus Alpha Cognition (NASDAQ:ACOG)

June 12, 2025 | americanbankingnews.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Sees Large Growth in Short Interest

June 2, 2025 | marketbeat.com

Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 16, 2025 | finanznachrichten.de

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 15, 2025 | globenewswire.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 5.10%

May 15, 2025 | aaii.com

Tenaya Therapeutics to Present Five Abstracts on Innovative Heart Disease Gene Therapies at ASGCT 2025 Annual Meeting

May 15, 2025 | nasdaq.com

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

May 13, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Stevanato Group (STVN) and Tenaya Therapeutics (TNYA)

May 11, 2025 | theglobeandmail.com

We're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate

May 10, 2025 | finance.yahoo.com

Tenaya Therapeutics Reports Q1 2025 Financial Results

May 8, 2025 | tipranks.com

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025 | finance.yahoo.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 5.03%

May 2, 2025 | aaii.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 6.21%

April 30, 2025 | aaii.com

H.C. Wainwright maintains Buy on Tenaya Therapeutics stock

April 26, 2025 | investing.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 6.36%

April 26, 2025 | aaii.com

Tenaya announces interim data from ongoing RIDGE study

April 25, 2025 | markets.businessinsider.com

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

April 24, 2025 | globenewswire.com

Tenaya Slashes a Third of Workforce to Fund Development of Cardio Gene Therapies

April 1, 2025 | biospace.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 11.06%

April 1, 2025 | aaii.com

Tenaya data further builds TN-201 profile, says H.C. Wainwright

April 1, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA, CRVS, FHTX, and INMB Company Descriptions

Corvus Pharmaceuticals NASDAQ:CRVS

$4.26 +0.07 (+1.67%)

Closing price 04:00 PM Eastern

Extended Trading

$4.20 -0.05 (-1.29%)

As of 07:55 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Foghorn Therapeutics NASDAQ:FHTX

$4.39 +0.07 (+1.62%)

Closing price 04:00 PM Eastern

Extended Trading

$4.39 0.00 (0.00%)

As of 04:04 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

INmune Bio NASDAQ:INMB

$8.02 +0.32 (+4.16%)

Closing price 04:00 PM Eastern

Extended Trading

$7.87 -0.15 (-1.86%)

As of 07:25 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Tenaya Therapeutics NASDAQ:TNYA

$0.62 +0.03 (+5.21%)

Closing price 04:00 PM Eastern

Extended Trading

$0.62 -0.01 (-1.17%)

As of 07:55 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time